Chongliang Luo

Chongliang Luo

Auto-generated profile, based on publicly available information

Chongliang Luo

Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis , St. Louis, MO, 63110

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in Statistics in Medicine
Verified
Journal Article
Closed access
CLChongliang Luo
Chongliang Luo
AMArielle Marks‐Anglin
Arielle Marks‐Anglin
RDRui Duan
Rui Duan
LLLifeng Lin
Lifeng Lin
CHChuan Hong
Chuan Hong
YCYong Chen
Yong Chen

12 October 2021 in medRxiv
Verified
Preprint
Open access
PDF file
KLKatharine Mn Lee
Katharine Mn Lee
EJEleanor J Junkins
Eleanor J Junkins
CLChongliang Luo
Chongliang Luo
UFUrooba A Fatima
Urooba A Fatima
MCMaria L Cox
Maria L Cox
KCKathryn Bh Clancy
Kathryn Bh Clancy
Many people began sharing that they experienced unexpected menstrual bleeding after SARS-CoV-2 inoculation. This emerging phenomenon was undeniable yet understudied. We investigated menstrual bleeding patterns among currently and formerly menstruating people, with a research design based off our expectations that these bleeding changes related to changes in clotting or inflammation, affecting normal menstrual repair. In this sample, 42% of people with regular menstrual cycles bled more heavily than usual, while 44% reported no change, after being vaccinated. Among people who typically do not menstruate, 71% of people on long-acting reversible contraceptives, 39% of people on gender-affirming hormones, and 66% of post-menopausal people reported breakthrough bleeding. We found increased/breakthrough bleeding was significantly associated with age, other vaccine side effects (fever, fatigue), history of pregnancy or birth, and ethnicity. Changes to menstrual bleeding are not uncommon nor dangerous, yet attention to these experiences is necessary to build trust in medicine. Teaser Increased bleeding can occur post SARS-CoV-2 vaccines; this study characterizes patterns to enable future hypothesis testing.

30 June 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CLChongliang Luo
Chongliang Luo
KCKun Chen
Kun Chen
RDRiddhi Doshi
Riddhi Doshi
NRNathaniel Rickles
Nathaniel Rickles
YCYong Chen
Yong Chen
RARobert H. Aseltine
Robert H. Aseltine
Background: Suicides and opioid overdose deaths are among the most pressing public health concerns in the US. However direct evidence for the association between opioid use and suicidal behavior is limited. The objective of this article is to examine the association between frequency and dose of prescription opioid use and subsequent suicide attempts.Methods and findings: This retrospective cohort study analyzed 4 years of statewide medical claims data from the Connecticut All-Payer Claims Database. Commercially insured adult patients in Connecticut (n = 842,773) who had any medical claims beginning in January 2012 were followed through December 2015. The primary outcome was suicide attempt identified using International Classification of Diseases (ICD 9) diagnosis codes. Primary predictor variables included frequency of opioid use, which was defined as the number of months with claims for prescription opioids per year, and strength of opioid dose, which was standardized using morphine milligram equivalent (MME) units. We also controlled for psychiatric and medical comorbidities using ICD 9 codes. We used Cox proportional hazards regression to examine the association between frequency, dose, and suicide attempts, adjusting for medical and psychiatric comorbid conditions. Interactions among measures of opioid use and comorbid conditions were analyzed.In this cohort study with follow-up time up to 4 years (range = 2–48 months, median = 46 months), the hazard ratios (HR) from the time-to-event analysis indicated that patients prescribed opioid medications for at least 6 months during the past year and at 20–50 MME levels or higher had 4.44 (95% CI: [3.71, 5.32]) to 7.23 (95% CI: [6.22, 8.41]) times the risk of attempted suicide compared to those not prescribed opioids. Risk of suicide attempt was sharply elevated among patients with psychiatric conditions other than anxiety who were prescribed more frequent and higher opioid doses. In contrast, more frequent and higher doses of prescription opioids were associated with lower risk of suicide attempts among patients with medical conditions necessitating pain management.This study is limited by its exclusive focus on commercially insured patients and does not include patients covered by public insurance. It is also limited to patients’ receipt of prescription opioids and does not take into account opioids obtained through other means, nor does it include measures of actual patient opioid use.Conclusions: This analysis provides evidence of a complex relationship among prescription opioids, mental health, pain and other medical comorbidities, and suicide risk. Findings indicate the need for proactive suicide surveillance among individuals diagnosed with affective or psychotic disorders who are receiving frequent and high doses of opioids. However, appropriate opioid treatment may have significant value in reducing suicide risk for those without psychiatric comorbidities.

5 December 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
CLChongliang Luo
Chongliang Luo
SKSaira Khan
Saira Khan
LJLiyan Jin
Liyan Jin
AJAimee S. James
Aimee S. James
GCGraham A Colditz
Graham A Colditz
BDBettina Drake
Bettina Drake
Background: Identifying changes in geographic disparities of cancer mortality reveals locations where cancer prevention and control efforts should be focused/targeted. We use recent cancer surveillance data to demonstrate the geographic disparity of major cancer mortality rates in the United States and its shift compared with previous data. Methods: This cross-sectional study used the 2018 to 2022 county-level mortality rates of colorectal, lung, breast, and prostate cancers from the Centers for Disease Control mortality data. Counties with suppressed death counts were imputed by spatial regression models. Getis–Ord Gi* statistics were used to evaluate the spatial clustering of county mortality. Identified hotspot counties were visualized and compared with literature for hotspot pattern change. Results: A total of 3,108 US mainland counties were included. Cancer mortality rates were significantly higher in 244 counties for colorectal, 456 for lung, 147 for breast, and 180 for prostate cancers. Hotspot areas were central Appalachia (colorectal and lung cancers), Lower Mississippi Delta (colorectal, breast, and prostate cancers), Midwest (colorectal and lung cancers), north Michigan/Wisconsin (lung and prostate cancers), north Florida (lung cancer), and the West (prostate cancer). Conclusions: West central Appalachia and Lower Mississippi Delta continue to be hotspots for major cancer types, whereas previously identified eastern North Carolina/Virginia hotspots shrunk, east Oklahoma and North Florida emerged as new hotspots for lung cancer, and several hotspots emerged in the West for prostate cancer. Impact: This study updated the analyses for geospatial disparity in major cancer mortality since 2018, illustrating recent changes in the disparity pattern and pinpointing areas that cancer prevention and control efforts should target.

19 January 2024 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
DZDazheng Zhang
Dazheng Zhang
JTJiayi Tong
Jiayi Tong
RSRonen Stein
Ronen Stein
YLYiwen Lu
Yiwen Lu
NJNaimin Jing
Naimin Jing
YCYong Chen
Yong Chen

2 February 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
CLChongliang Luo
Chongliang Luo
YJYing Jiang
Ying Jiang
JDJingcheng Du
Jingcheng Du
JTJiayi Tong
Jiayi Tong
JHJing Huang
Jing Huang
YCYong Chen
Yong Chen
Purpose: Severe adverse events (AEs), such as Guillain‐Barré syndrome (GBS) occur rarely after influenza vaccination. We identify highly associated AEs with GBS and develop prediction models for GBS using the US Vaccine Adverse Event Reporting System (VAERS) reports following trivalent influenza vaccination (FLU3).Methods: This study analyzed 80 059 reports from the US VAERS between 1990 and 2017. Several AEs were identified as highly associated with GBS and were used to develop the prediction model. Some common and mild AEs that were suspected to be underreported when GBS occurred simultaneously were removed from the final model. The analyses were validated using European influenza vaccine AEs data from EudraVigilance.Results: Of the 80 059 reports, 1185 (1.5%) were annotated as GBS related. Twenty‐four AEs were identified as having strong association with GBS. The full prediction model, using age, sex, and all 24 AEs achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 85.4% (90% CI: [83.8%, 86.9%]). After excluding the nine (e.g., pruritus, rash, injection site pain) likely underreported AEs, the final AUC became 77.5% (90% CI: [75.5%, 79.6%]). Two hundred and one (0.25%) reports were predicted as of high risk of GBS (predicted probability >25%) and 84 actually developed GBS.Conclusion: The prediction performance demonstrated the potential of developing risk‐prediction models utilizing the VAERS cohort. Excluding the likely underreported AEs sacrificed some prediction power but made the model more interpretable and feasible. The high absolute risk of even a small number of AE combinations suggests the promise of GBS prediction within the VAERS dataset.